Vor Biopharma's Lead Hematopoietic Stem Cell Candidate Fast Tracked In US

Vor Biopharma's Lead Hematopoietic Stem Cell Candidate Fast Tracked In US
  • The FDA has granted Fast Track designation to Vor Biopharma's VOR VOR33, lead engineered hematopoietic stem cell (eHSC) therapeutic candidate for acute myeloid leukemia (AML).
  • VOR33 consists of CRISPR genome-edited hematopoietic stem and progenitor cells that have been engineered to lack CD33.
  • The Company is enrolling in its Phase 1/2a trial for AML patients and remains on track to report initial data in 1H of FY22.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: VOR stock is 4.04% at $16.22 during the market session on the last check Thursday.

Posted In: acute myeloid leukemiaBriefsPhase 1 TrialBiotechNewsHealth CareSmall CapFDAMoversTrading IdeasGeneral